A Multi-Center, Randomized, Placebo-Controlled Phase II Study Of Regorafenib In Combination With Folfiri (Irinotecan, 5-Fluorouracil, And Leucovorin)
Posted Date: May 15, 2019
- Investigator: Olugbenga Olowokure
- Type of Study: Drug
This study is to assess if regorafenib when given in combination with FOLFIRI chemotherapy will result in increased survival without cancer getting worse as compared to a non-active treatment given in combination with FOLFIRI. Patients will continue to receive the study drug and chemotherapy as long
Criteria:
Eligible Patients Must Have Been Diagnosed With Colorectal Cancer That Has Spread Outside Of The Col
Keywords:
Colorectal Cancer, Gastroinestinal, K-Ras, Lccc 1029, Metastatic
For More Information:
Uc Cancer Center
513-584-7698
kastla@ucmail.uc.edu